Bladder Cancer
Prostate Cancer
EAU Edu Platform on Kidney Cancer
Home
Articles
Article of the Month
Editorials
Videos
Webcasts
Education
E-courses
Webinars
Online curriculum
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorials
Videos
Webcasts
Education
Terug
E-courses
Webinars
Online curriculum
Guidelines
Events
Upcoming event
40th Annual EAU Congress
Home
/
Articles
Back
EAU2023
ASCO GU2023
ESMO22
EAU2022
AUA2022
ASCO GU2022
ASCO21
Article of the Month
Filter
Tags
Article of the Month
,
ASCO GU22
,
ASCO21
,
AUA21
,
Cabozantinib
,
Carcinoma
,
Chronic kidney disease
,
Cryosurgery
,
EAU
,
EAU21
,
EAU22
,
EMUC21
,
EMUC22
,
ERUS22
,
ESMO21
,
Frail patient
,
Glomerular filtration rate
,
Guidelines
,
IMDC risk model
,
Kidney cancer
,
Laparoscopy
,
Lymph node metastases
,
Lymph nodes
,
Metastasectomy
,
Mortality
,
Neoplasm metastasis
,
Neoplasm recurrence
,
Nephrectomy
,
Nephron-sparing surgery
,
Nivolumab
,
Overall survival
,
Partial nephrectomy
,
Prognostication
,
Radical nephrectomy
,
Radical surgery
,
RCC
,
Renal cancer
,
Renal cell
,
Renal cell carcinoma
,
Renal Cell Carcinoma guidelines
,
Renal cryoablation
,
Renal function
,
Renal Transplantation
,
Renorrhaphy
,
Robotic
,
Robotic prostatectomy
,
Robotic surgery
,
Survival outcome
,
Suture
,
Targeted therapies
,
Treatment response
,
Urological surgery
,
UROonco24
,
UROwebinar
,
Webinar
Show all
Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time
View
Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma
European Urology Oncology, October 2022
View
Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma
View
Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups
European Urology Open Science, January 2023
View
Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups
View
Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies
European Urology Oncology, December 2022
View
Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies
View
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
British Journal of Cancer, June 2022
View
Development and validation of a nomogram predicting intraoperative adverse events during robot-assisted partial nephrectomy
European Urology Focus, September 2022
View
Stereotactic ablative radiation for systemic therapy–naïve oligometastatic kidney cancer
European Urology Oncology, August 2022
View
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
The Lancet Oncology, May 2022
View
What happens to the preserved renal parenchyma after clamped partial nephrectomy?
European Urology, May 2022
View
Previous
Next